Technology
Health
Biotechnology

Cellectar Biosciences

$2.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-2.33%) Today
+$0.05 (2.38%) As of 5:26 PM EDT after-hours

Why Robinhood?

You can buy or sell CLRB and other stocks, options, ETFs, and crypto commission-free!

About CLRB

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. Read More The company was founded in June,1996 and is headquartered in Florham Park, NJ.

Employees
7
Headquarters
Florham Park, New Jersey
Founded
1996
Market Cap
10.68M
Price-Earnings Ratio
Dividend Yield
Average Volume
187.50K
High Today
$2.14
Low Today
$2.07
Open Price
$2.14
Volume
121.43K
52 Week High
$7.15
52 Week Low
$1.22

Collections

Technology
Health
Biotechnology
Cancer Prevention
Medical
2018 IPO
US
North America

CLRB News

MarketWatchJul 5

Cellectar Biosciences Inc. Wt Series A

59

CLRB Earnings

-$2.10
-$1.38
-$0.66
$0.06
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market

More CLRB News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.